Jazz Pharmaceuticals (JAZZ) PT Lowered to $113 at Piper Sandler As Diagnoses Are Delayed
Tweet Send to a Friend
Piper Sandler analyst David Amsellem lowered the price target on Jazz Pharmaceuticals (NASDAQ: JAZZ) to $113.00 (from $127.00) ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
